SG Americas Securities
EVLO

SG Americas Securities’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

SG Americas Securities’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-523
Closed -$74K – 3937
2021
Q3 		$74K Buy
+523
New +$104K ﹤0.01% 3702

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SG Americas Securities's EVLO Position: Q4 2021 in Review

SG Americas Securities sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2021, closing a stake of 523 shares — an estimated $74K sold.

SG Americas Securities first reported a position in EVLO in Q3 2021 and held it in 1 quarter. The position peaked at $74K in Q3 2021. 66 funds tracked by Wall St. Rank hold EVLO as of Q4 2021.

  • SG Americas Securities reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • SG Americas Securities sold 523 Evelo Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $74K.
  • SG Americas Securities first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • SG Americas Securities's Evelo Biosciences, Inc. Common Stock position peaked at $74K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2021.

Based on SG Americas Securities's 13F filing for Q4 2021, filed 7 Feb 2022.